Clinical oncology最新文献_第4页

Virtual follow-up after prostate radiotherapy: A successful model utilising non-clinical personnel to streamline care and optimise patient outcomes

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.016

S. Dipro, S. Appleyard

引用次数: 0

Prospective analysis of patient reported outcomes following rectal spacer insertion prior to Prostate radiotherapy

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.017

M. Hughes, K.D. Linton, A. Sykes, D.P. Rosario, O.S. Din

引用次数: 0

A sub-study to assess the agreement between the anti-cancer treatment records in Systemic Anticancer Therapy (SACT) and Hospital Episode Statistics (HES) database from a large-scale retrospective cohort study with patients with renal cell carcinoma in England

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.012

M. Ling , P. Das , A. Clark , L. Vaz , A. Booth , R. Das

引用次数: 0

Chemotherapy tolerance and outcomes in geriatric breast cancer patients aged >70 assessed using the Edmonton Frail Scale

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103723

S. Mumtaz , R. Muhammad , N. Goyal , A. Konstantis

引用次数: 0

Developing a Paired Whole Genome Sequencing Service for Children With Cancer 为癌症儿童开发配对全基因组测序服务。

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.07.009

L. Sarkies , P. Thomas , E.A. Edeko , S. Leiter , J. Trotman , R. Armstrong , A. Vedi

{"title":"Developing a Paired Whole Genome Sequencing Service for Children With Cancer","authors":"L. Sarkies , P. Thomas , E.A. Edeko , S. Leiter , J. Trotman , R. Armstrong , A. Vedi","doi":"10.1016/j.clon.2024.07.009","DOIUrl":"10.1016/j.clon.2024.07.009","url":null,"abstract":"<div><h3>Background</h3><div>The uniqueness of paired (tumor and germline) whole genome sequencing (PWGS) in cancer diagnosis and management lies in not just its ability to uncover oncogenic drivers and potential treatment targets but also on the identification of underlying cancer predisposition syndromes, which has significant implications for the patient and their family.</div></div><div><h3>Aims</h3><div>This is a descriptive article highlighting the processes taken by our team to incorporate PWGS into routine National Health Service (NHS) clinical care for children with cancer. The main aim of this article is to share our experience with other centers that may wish to set up similar services and set the stage for future quantitative/qualitative research.</div></div><div><h3>Methods</h3><div>This article is further supported by an audit focusing on children in whom an underlying cancer predisposition was confirmed.</div></div><div><h3>Results</h3><div>The audit highlights the success of the program to date, with 100% of families identified as being at risk of a cancer predisposition syndrome being offered referral to clinical genetics and 100% of at-risk first-degree relatives being offered predictive counseling and testing. Areas requiring improvement included discussion of reproductive options as only six out of nine families (67%) had a documented discussion.</div></div><div><h3>Conclusions</h3><div>Incorporation of the audit recommendations will improve our service, and sharing of our experience will hopefully encourage more pediatric oncology services to introduce PWGS into routine clinical care and reduce inequity of access. Further work is required to assess the long-term cancer risk reduction and establish the psychosocial impact of PWGS for the child and family.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103623"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care 宪法基因组检测对当前乳腺癌治疗的临床影响。

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.08.006

W. Cheah, R.I. Cutress, D. Eccles, E. Copson

{"title":"Clinical Impact of Constitutional Genomic Testing on Current Breast Cancer Care","authors":"W. Cheah, R.I. Cutress, D. Eccles, E. Copson","doi":"10.1016/j.clon.2024.08.006","DOIUrl":"10.1016/j.clon.2024.08.006","url":null,"abstract":"<div><div>The most commonly diagnosed cancer in women worldwide is cancer of the breast. Up to 20% of familial cases are attributable to pathogenic mutations in high-penetrance (BReast CAncer gene 1 [BRCA1], BRCA2, tumor protein p53 [TP53], partner and localizer of breast cancer 2 [PALB2]) or moderate-penetrance (checkpoint kinase 2 [CHEK2], Ataxia-telangiectasia mutated [ATM], RAD51C, RAD51D) breast-cancer-predisposing genes. Most of the breast-cancer-predisposing genes are involved in DNA damage repair via homologous recombination pathways. Understanding these pathways can facilitate the development of risk-reducing and therapeutic strategies. The number of breast cancer patients undergoing testing for pathogenic mutations in these genes is rapidly increasing due to various factors. Advances in multigene panel testing have led to increased detection of pathogenic mutation carriers at high risk for developing breast cancer and contralateral breast cancer. However, the lack of long-term clinical outcome data and incomplete understanding of variants, particularly for moderate-risk genes limits clinical application. In this review, we have summarized the key functions, risks, and prognosis of breast-cancer-predisposing genes listed in the National Health Service (NHS) England National Genomic Test Directory for inherited breast cancer and provide an update on current management implications including surgery, radiotherapy, systemic treatments, and post-treatment surveillance.</div></div>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"Article 103631"},"PeriodicalIF":3.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OncoFlash—Research Updates in a Flash! OncoFlash - 即时研究更新！

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.10.031

S. Parikh , K.T. Jayaprakash

引用次数: 0

Sequencing Targeted Therapy in Era of Precision Medicine for Thyroid Cancers 精准医学时代甲状腺癌的测序靶向治疗。

IF 3.2 3区医学

Clinical oncology Pub Date : 2025-02-01 DOI: 10.1016/j.clon.2024.103704

I.S. Boon

引用次数: 0

Exploring gene expression in localised prostate cancer: Insights from a randomised control trial with a focus on hypoxia and angiogenic genomic biomarkers post-EBRT and HDR-BTb